{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:27:08Z","timestamp":1791973628969,"version":"4.4.0"},"reference-count":80,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Primary systemic amyloidosis is an immunoglobulin light chain disorder that is 1\/5th as common as multiple myeloma. Amyloidosis is regularly seen in the practice of a hematologist and has recently undergone major advances in terms of the ability to evaluate responses as well as new therapeutic options that were not available when this topic was covered as an education session at the American Society of Hematology meeting 5 years ago. Waldenstro\u0308m macroglobulinemia (WM) is rarer than amyloidosis (1500 per year WM versus 3000 per year amyloid in the US), and recent consensus panels have established the definition of the disease, the diagnostic criteria, criteria for initiation of therapy and a new classification scheme. In this session, new developments in amyloid and macroglobulinemia, from suspicion of the diagnosis to treatment, are covered.<\/jats:p><jats:p>In Section I, Dr. Morie Gertz answers four specific questions: (1) When should amyloidosis be suspected? (2) How does one heighten ones index of suspicion for amyloid? (3) How is the diagnosis confirmed and the type classified as primary? (4) What is the prognosis and how is it accurately assessed? Recent findings on cardiac biomarkers, presenting features and use of the free light chain assay are reviewed. Staging for amyloid and recently proposed criteria of response and progression are covered.<\/jats:p><jats:p>In Section II, Dr. Giampaolo Merlini comprehensively reviews therapy of amyloidosis from the use of standard melphalan\/prednisone to the recently described standard dose therapies including dexamethasone, thalidomide\/dexamethasone, melphalan\/dexamethasone and IV melphalan\/dexamethasone. An extensive discussion of the role of high-dose therapy with stem cell reconstitution follows and includes patient selection, predictors of immediate morbidity and mortality, and survival expectation. Finally, a therapeuitc strategy is proposed.<\/jats:p><jats:p>In Section III, Drs. Steven Treon and Giampaolo Merlini review the most current information on WM. The consensus panel results and recommendations of the clinical pathologic definition of WM, the prognostic markers and the indications to initiate therapy in WM, the uniform response criteria in WM and available treatments for the disease are reviewed. Drs. Treon and Merlini cover recently published treatment protocols that use rituximab, purine nucleoside analogs, and alkylating agents. The current data on thalidomide, alpha interferon, and high-dose therapy are also covered.<\/jats:p>","DOI":"10.1182\/asheducation-2004.1.257","type":"journal-article","created":{"date-parts":[[2004,11,20]],"date-time":"2004-11-20T02:03:01Z","timestamp":1100916181000},"page":"257-282","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":65,"title":["Amyloidosis and Waldenstro\u0308m\u2019s Macroglobulinemia"],"prefix":"10.1182","volume":"2004","author":[{"given":"Morie A.","family":"Gertz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Merlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Treon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021215284037300_R1","doi-asserted-by":"crossref","unstructured":"Westermark P, Benson MD, Buxbaum JN, et al. Amyloid fibril protein nomenclature\u20142002. Amyloid. 2002;9(3):197\u2013200.","DOI":"10.3109\/13506120209114823"},{"key":"2020021215284037300_R2","doi-asserted-by":"crossref","unstructured":"Abraham RS, Katzmann JA, Clark RJ, Bradwell AR, Kyle RA, Gertz MA. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol. 2003;119(2):274\u2013278.","DOI":"10.1309\/LYWM47K2L8XYFFB3"},{"key":"2020021215284037300_R3","doi-asserted-by":"crossref","unstructured":"Swan N, Skinner M, O\u2019Hara CJ. Bone marrow core biopsy specimens in AL (primary) amyloidosis. A morphologic and immunohistochemical study of 100 cases. Am J Clin Pathol. 2003;120(4):610\u2013616.","DOI":"10.1309\/PFUGHBX0TY20E08U"},{"key":"2020021215284037300_R4","doi-asserted-by":"crossref","unstructured":"Hachulla E, Grateau G. Diagnostic tools for amyloidosis. Joint Bone Spine. 2002;69(6):538\u2013545.","DOI":"10.1016\/S1297-319X(02)00449-9"},{"key":"2020021215284037300_R5","doi-asserted-by":"crossref","unstructured":"Andrews TR, Colon-Otero G, Calamia KT, Menke DM, Boylan KB, Kyle RA. Utility of subcutaneous fat aspiration for diagnosing amyloidosis in patients with isolated peripheral neuropathy. Mayo Clin Proc. 2002;77(12):1287\u20131290.","DOI":"10.4065\/77.12.1287"},{"key":"2020021215284037300_R6","doi-asserted-by":"crossref","unstructured":"Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med. 2002;346(23):1786\u20131791.","DOI":"10.1056\/NEJMoa013354"},{"key":"2020021215284037300_R7","doi-asserted-by":"crossref","unstructured":"Benson MD. The hereditary amyloidoses [Review]. Best Pract Res Clin Rheumatol. 2003;17(6):909\u2013927.","DOI":"10.1016\/j.berh.2003.09.001"},{"key":"2020021215284037300_R8","doi-asserted-by":"crossref","unstructured":"Rocken C, Shakespeare A. Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch. 2002 Feb;440(2):111\u201322. Review.","DOI":"10.1007\/s00428-001-0582-9"},{"key":"2020021215284037300_R9","doi-asserted-by":"crossref","unstructured":"Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583\u2013596.","DOI":"10.1056\/NEJMra023144"},{"key":"2020021215284037300_R10","doi-asserted-by":"crossref","unstructured":"Arbustini E, Verga L, Concardi M, Palladini G, Obici L, Merlini G. Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. Amyloid. 2002;9(2):108\u2013114.","DOI":"10.3109\/13506120208995243"},{"key":"2020021215284037300_R11","doi-asserted-by":"crossref","unstructured":"Pardanani A, Witzig TE, Schroeder G, et al. Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. Blood. 2003;101(3):827\u2013830.","DOI":"10.1182\/blood-2002-06-1698"},{"key":"2020021215284037300_R12","doi-asserted-by":"crossref","unstructured":"Koyama J, Ray-Sequin PA, Falk RH. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation. 2003;107(19):2446\u20132452.","DOI":"10.1161\/01.CIR.0000068313.67758.4F"},{"key":"2020021215284037300_R13","doi-asserted-by":"crossref","unstructured":"Miller WL, Wright RS, McGregor CG, et al. Troponin levels in patients with amyloid cardiomyopathy undergoing cardiac transplantation. Am J Cardiol. 2001;88 (7):813\u2013815.","DOI":"10.1016\/S0002-9149(01)01877-X"},{"key":"2020021215284037300_R14","doi-asserted-by":"crossref","unstructured":"Dispenzieri A, Kyle RA, Gertz MA, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet. 2003;361(9371):1787\u20131789.","DOI":"10.1016\/S0140-6736(03)13396-X"},{"key":"2020021215284037300_R15","unstructured":"Dispenzieri A, Kyle RA, Lacy MQ, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplant: a case control study. Blood. 2004; First edition paper prepublished online March 25, 2004."},{"key":"2020021215284037300_R16","doi-asserted-by":"crossref","unstructured":"Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation. 2003;107(19):2440\u20132445.","DOI":"10.1161\/01.CIR.0000068314.02595.B2"},{"key":"2020021215284037300_R17","doi-asserted-by":"crossref","unstructured":"Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol. 2003;122(1):78\u201384.","DOI":"10.1046\/j.1365-2141.2003.04433.x"},{"key":"2020021215284037300_R18","doi-asserted-by":"crossref","unstructured":"Gertz MA, Lacy MQ, Dispenzieri A. Therapy for immunoglobulin light chain amyloidosis: the new and the old. Blood Rev. 2004;18(1):17\u201337.","DOI":"10.1016\/S0268-960X(03)00027-4"},{"key":"2020021215284037300_R19","doi-asserted-by":"crossref","unstructured":"Myers B, Lachmann H, Russell NH. Novel combination chemotherapy for primary (AL) amyloidosis myeloma: clinical, laboratory and serum amyloid-P protein scan improvement. Br J Haematol. 2003;121(5):816\u2013817.","DOI":"10.1046\/j.1365-2141.2003.04352.x"},{"key":"2020021215284037300_R20","doi-asserted-by":"crossref","unstructured":"Gertz MA, Lacy MQ, Dispenzieri A, et al. Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med. 2002;113(7):549\u2013555.","DOI":"10.1016\/S0002-9343(02)01208-1"},{"key":"2020021215284037300_R21","doi-asserted-by":"crossref","unstructured":"Dispenzieri A, Lacy MQ, Kyle RA, et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol. 2001;19(14):3350\u20133356.","DOI":"10.1200\/JCO.2001.19.14.3350"},{"key":"2020021215284037300_R22","doi-asserted-by":"crossref","unstructured":"Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349:583\u2013596.","DOI":"10.1056\/NEJMra023144"},{"key":"2020021215284037300_R23","doi-asserted-by":"crossref","unstructured":"Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood. 2002;99:4276\u20134282.","DOI":"10.1182\/blood.V99.12.4276"},{"key":"2020021215284037300_R24","doi-asserted-by":"crossref","unstructured":"Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8-year study. Ann Intern Med. 2004;140:85\u201393.","DOI":"10.7326\/0003-4819-140-2-200401200-00008"},{"key":"2020021215284037300_R25","doi-asserted-by":"crossref","unstructured":"Gertz MA, Lacy MQ, Dispenzieri A, et al. Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med. 2002;113:549\u2013555.","DOI":"10.1016\/S0002-9343(02)01208-1"},{"key":"2020021215284037300_R26","doi-asserted-by":"crossref","unstructured":"Sanchorawala V, Wright DG, Seldin DC, et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant. 2001;28:637\u2013642.","DOI":"10.1038\/sj.bmt.1703200"},{"key":"2020021215284037300_R27","doi-asserted-by":"crossref","unstructured":"Sanchorawala V, Wright DG, Seldin DC, et al. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplant. 2004;33:381\u2013388.","DOI":"10.1038\/sj.bmt.1704346"},{"key":"2020021215284037300_R28","doi-asserted-by":"crossref","unstructured":"Blum W, Khoury H, Lin HS, et al. Primary amyloidosis patients with significant organ dysfunction tolerate autologous transplantation after conditioning with single-dose total body irradiation alone: a feasibility study. Biol Blood Marrow Transplant. 2003;9:397\u2013404.","DOI":"10.1016\/S1083-8791(03)00106-X"},{"key":"2020021215284037300_R29","doi-asserted-by":"crossref","unstructured":"Dispenzieri A, Kyle RA, Lacy MQ, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood2004;103:3960\u20133963.","DOI":"10.1201\/9781420037494-43"},{"key":"2020021215284037300_R30","doi-asserted-by":"crossref","unstructured":"Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997;336:1202\u20131207.","DOI":"10.1056\/NEJM199704243361702"},{"key":"2020021215284037300_R31","doi-asserted-by":"crossref","unstructured":"Bird J, Cavenagh J, Hawkins P, et al. Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol. 2004;125:681\u2013700.","DOI":"10.1111\/j.1365-2141.2004.04970.x"},{"key":"2020021215284037300_R32","doi-asserted-by":"crossref","unstructured":"Gertz MA, Lacy MQ, Lust JA, et al. Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. J Clin Oncol. 1999;17:262\u2013267.","DOI":"10.1200\/JCO.1999.17.1.262"},{"key":"2020021215284037300_R33","doi-asserted-by":"crossref","unstructured":"Dhodapkar M, Hussein MA, Rasmussen E, et al. Clinical efficacy of high dose dexamethasone with maintenance dexamethasone\/alpha interferon in patients with primary systemic amyloidosis: results of United States intergroup trial Southwest Oncology Group (SWOG) S9628. Blood. 2004. In press.","DOI":"10.1182\/blood-2004-05-1924"},{"key":"2020021215284037300_R34","doi-asserted-by":"crossref","unstructured":"Palladini G, Anesi E, Perfetti V, et al. A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. Br J Haematol. 2001;113:1044\u20131046.","DOI":"10.1046\/j.1365-2141.2001.02859.x"},{"key":"2020021215284037300_R35","doi-asserted-by":"crossref","unstructured":"Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004;103:2936\u20132938.","DOI":"10.1182\/blood-2003-08-2788"},{"key":"2020021215284037300_R36","doi-asserted-by":"crossref","unstructured":"Seldin DC, Choufani EB, Dember LM, et al. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin Lymphoma. 2003;3:241\u2013246.","DOI":"10.3816\/CLM.2003.n.005"},{"key":"2020021215284037300_R37","doi-asserted-by":"crossref","unstructured":"Dispenzieri A, Lacy MQ, Rajkumar SV, et al. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid. 2003;10:257\u2013261.","DOI":"10.3109\/13506120309041743"},{"key":"2020021215284037300_R38","doi-asserted-by":"crossref","unstructured":"Hussein MA, Juturi JV, Rybicki L, et al. Etanercept therapy in patients with advanced primary amyloidosis. Med Oncol. 2003;20:283\u2013290.","DOI":"10.1385\/MO:20:3:283"},{"key":"2020021215284037300_R39","doi-asserted-by":"crossref","unstructured":"Hrncic R, Wall J, Wolfenbarger DA, et al. Antibody-mediated resolution of light chain-associated amyloid deposits. Am J Pathol. 2000;157:1239\u20131246.","DOI":"10.1016\/S0002-9440(10)64639-1"},{"key":"2020021215284037300_R40","doi-asserted-by":"crossref","unstructured":"Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol. 2003;122:78\u201384.","DOI":"10.1046\/j.1365-2141.2003.04433.x"},{"key":"2020021215284037300_R41","doi-asserted-by":"crossref","unstructured":"Mollee PN, Wechalekar AD, Pereira DL, et al. Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome. Bone Marrow Transplant. 2004;33:271\u2013277.","DOI":"10.1038\/sj.bmt.1704344"},{"key":"2020021215284037300_R42","doi-asserted-by":"crossref","unstructured":"Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstro\u0308m\u2019s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstro\u0308m\u2019s macroglobulinemia. Semin Oncol. 2003;30:110\u2013115.","DOI":"10.1053\/sonc.2003.50082"},{"key":"2020021215284037300_R43","doi-asserted-by":"crossref","unstructured":"Manning R, Branagan AR, Hunter Z, Tournilhac O, Santos DD, Treon SP. Characterization of familial Waldenstrom\u2019s macroglobulinemia. J Clin Oncol. 2003;22:572s.","DOI":"10.1200\/jco.2004.22.14_suppl.6558"},{"key":"2020021215284037300_R44","doi-asserted-by":"crossref","unstructured":"Schop RF, Kuehl WM, Van Wier SA, et al. Waldenstro\u0308m macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood. 2002;100:2996\u20133001.","DOI":"10.1182\/blood.V100.8.2996"},{"key":"2020021215284037300_R45","unstructured":"Treon SP, Braverman E, Branagan AR, et al. Deletions in 6q21-22 are commonly present in patients with familial and non-familial Waldenstrom\u2019s macroglobulinemia and IgM monoclonal gammopathy of unknown significance [abstract]. Blood. 102:682a."},{"key":"2020021215284037300_R46","doi-asserted-by":"crossref","unstructured":"Avet-Loiseau H, Garand R, Lode L, Robillard N, Bataille R. 14q32 translocations discriminate IgM multiple myeloma from Waldenstrom\u2019s macroglobulinemia. Semin Oncol. 2003;30:153\u2013155.","DOI":"10.1053\/sonc.2003.50053"},{"key":"2020021215284037300_R47","doi-asserted-by":"crossref","unstructured":"Smith BR, Robert NJ, Ault KA. In Waldenstrom\u2019s macroglobulinemia the quantity of detectable circulating monoclonal B lymphocytes correlates with clinical course. Blood. 1983;61:911\u2013914.","DOI":"10.1182\/blood.V61.5.911.911"},{"key":"2020021215284037300_R48","doi-asserted-by":"crossref","unstructured":"Owen RG, Barrans SL, Richards SJ, et al. Waldenstro\u0308m macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors. Am J Clin Pathol. 2001; 116:420\u2013428.","DOI":"10.1309\/4LCN-JMPG-5U71-UWQB"},{"key":"2020021215284037300_R49","doi-asserted-by":"crossref","unstructured":"San Miguel JF, Vidriales MB, Ocio E, et al. Immunophenotypic analysis of Waldenstrom\u2019s macroglobulinemia. Semin Oncol. 2003;30:187\u2013195.","DOI":"10.1053\/sonc.2003.50074"},{"key":"2020021215284037300_R50","doi-asserted-by":"crossref","unstructured":"Cafarella T, Manning R, Hunter Z, et al. Heterogeneous expression of CD5, CD10, and CD23 in IgM secreting lymphoplasmacytic lymphoma (Waldenstrom\u2019s macroglobulinemia) [abstract]. J Clin Oncol. 2004;22:614s.","DOI":"10.1200\/jco.2004.22.14_suppl.6730"},{"key":"2020021215284037300_R51","doi-asserted-by":"crossref","unstructured":"Wagner SD, Martinelli V, Luzzatto L. Similar patterns of V kappa gene usage but different degrees of somatic mutation in hairy cell leukemia, prolymphocytic leukemia, Waldenstro\u0308m\u2019s macroglobulinemia, and myeloma. Blood. 1994;83:3647\u20133653.","DOI":"10.1182\/blood.V83.12.3647.3647"},{"key":"2020021215284037300_R52","doi-asserted-by":"crossref","unstructured":"Aoki H, Takishita M, Kosaka M, Saito S. Frequent somatic mutations in D and\/or JH segments of Ig gene in Waldenstro\u0308m\u2019s macroglobulinemia and chronic lymphocytic leukemia (CLL) with Richter\u2019s syndrome but not in common CLL. Blood. 1995;85:1913\u20131919.","DOI":"10.1182\/blood.V85.7.1913.bloodjournal8571913"},{"key":"2020021215284037300_R53","doi-asserted-by":"crossref","unstructured":"Sahota SS, Forconi F, Ottensmeier CH, et al. Typical Waldenstro\u0308m macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events. Blood. 2002;100:1505\u20131507.","DOI":"10.1182\/blood.V100.4.1505.h81602001505_1505_1507"},{"key":"2020021215284037300_R54","doi-asserted-by":"crossref","unstructured":"Kriangkum J, Taylor BJ, Treon SP, Mant MJ, Belch AR, Pilarski LM. Clonotypic IgH VDJ sequence analysis in Waldenstrom\u2019s macroglobulinemia suggests an unusual B cell origin and expansion of polyclonal B cells in peripheral blood. Blood. 2004. In press.","DOI":"10.1182\/blood-2003-11-4024"},{"key":"2020021215284037300_R55","doi-asserted-by":"crossref","unstructured":"San Miguel JF, Vidriales MB, Ocio E, et al. Immunophenotypic analysis of Waldenstrom\u2019s macroglobulinemia. Semin Oncol. 2003;30:187\u2013195.","DOI":"10.1053\/sonc.2003.50074"},{"key":"2020021215284037300_R56","doi-asserted-by":"crossref","unstructured":"Tournilhac O, Ditzel Santos D, Branagan AR, et al. Excess bone marrow mast cells constititvely express CD154 (CD40 ligand) in Waldenstrom\u2019s macroglobulinemia and may support tumor cell growth through CD154\/CD40 pathway [abstract]. J Clin Oncol. 22:571s.","DOI":"10.1200\/jco.2004.22.14_suppl.6555"},{"key":"2020021215284037300_R57","doi-asserted-by":"crossref","unstructured":"Merlini G, Baldini L, Broglia C, et al. Prognostic factors in symptomatic Waldenstro\u0308m\u2019s macroglobulinemia. Semin Oncol. 2003;30:211\u2013215.","DOI":"10.1053\/sonc.2003.50064"},{"key":"2020021215284037300_R58","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Alexanian R. Waldenstro\u0308m\u2019s macroglobulinemia. Blood. 1994;83:1452\u20131459.","DOI":"10.1182\/blood.V83.6.1452.1452"},{"key":"2020021215284037300_R59","doi-asserted-by":"crossref","unstructured":"Bartl R, Frisch B, Mahl G, et al. Bone marrow histology in Waldenstro\u0308m\u2019s macroglobulinaemia. Clinical relevance of subtype recognition. Scand J Haematol. 1983;31:359\u2013375.","DOI":"10.1111\/j.1600-0609.1983.tb00664.x"},{"key":"2020021215284037300_R60","doi-asserted-by":"crossref","unstructured":"Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenstro\u0308m\u2019s macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstro\u0308m\u2019s macroglobulinemia. Semin Oncol. 2003;30:116\u2013120.","DOI":"10.1053\/sonc.2003.50038"},{"key":"2020021215284037300_R61","doi-asserted-by":"crossref","unstructured":"Gertz M, Anagnostopoulos A, Anderson KC, et al. Treatment recommendations in Waldenstro\u0308m\u2019s macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstro\u0308m\u2019s macroglobulinemia. Semin Oncol. 2003;30:121\u2013126.","DOI":"10.1053\/sonc.2003.50039"},{"key":"2020021215284037300_R62","doi-asserted-by":"crossref","unstructured":"Merlini G, Treon SP. Waldenstrom\u2019s disease. In: Multiple Myeloma and Related Disorders. Gahrton G, Durie B, Samson DM, editors. Oxford University Press Inc., New York N.Y. 2004.","DOI":"10.1201\/b13347-36"},{"key":"2020021215284037300_R63","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Kantarjian H, Weber D, et al. Primary therapy of Waldenstro\u0308m\u2019s macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol. 1994;12:2694\u20132698.","DOI":"10.1200\/JCO.1994.12.12.2694"},{"key":"2020021215284037300_R64","doi-asserted-by":"crossref","unstructured":"Liu ES, Burian C, Miller WE, Saven A. Bolus administration of cladribine in the treatment of Waldenstro\u0308m macroglobulinaemia. Br J Haematol. 1998;103:690\u2013695.","DOI":"10.1046\/j.1365-2141.1998.01069.x"},{"key":"2020021215284037300_R65","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenstrom\u2019s macroglobulinemia with rituximab. J Clin Oncol. 2002;20:2327\u20132333.","DOI":"10.1200\/JCO.2002.09.039"},{"key":"2020021215284037300_R66","unstructured":"Treon SP, Emmanouilides CA, Kimby E, et al. Extended rituximab in Waldenstrom\u2019s macroglobulinemia. Ann Oncol. 2004. In press."},{"key":"2020021215284037300_R67","unstructured":"Treon SP, Branagan AR, Anderson KC. Paradoxical increases in serum IgM levels and serum viscosity following rituximab therapy in patients with Waldenstrom\u2019s macroglobulinemia [abstract]. Blood. 2003;102:690a."},{"key":"2020021215284037300_R68","unstructured":"Ghobrial IM, Fonseca R, Greipp PR, et al. The initial \u201cflare\u201d of IgM level after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: An Eastern Cooperative Oncology Group Study. Blood. 2003;102:448a."},{"key":"2020021215284037300_R69","unstructured":"Treon SP, Fox EA, Hansen MM, et al. Polymorphism in Fc gamma RIIIa (CD16) receptor expression are associated with clinical responses in Waldenstro\u0308m\u2019s macroglobulinemia [abstract]. Blood. 2002;100:773a."},{"key":"2020021215284037300_R70","doi-asserted-by":"crossref","unstructured":"Weber DM, Dimopoulos MA, Delasalle K, Rankin K, Gavino M, Alexanian R. 2-Chlorodeoxyadenosine (2-CdA) alone or in combination for previously untreated Waldenstro\u0308m\u2019s macroglobulinemia. Semin Oncol. 2003;30:243\u2013247.","DOI":"10.1053\/sonc.2003.50070"},{"key":"2020021215284037300_R71","unstructured":"Treon SP, Wasi P, Emmanoulilides C, et al. Combination therapy with rituximab and fludarabine is highly active in Waldenstrom\u2019s macroglobulinemia [abstract]. Blood. 2002;100:211a."},{"key":"2020021215284037300_R72","unstructured":"Owen RG, Rawstron AC, Osterborg A, et al. Activity of alemtuzumab in relapsed\/refractory Waldenstrom\u2019s macroglobulinemia. Blood. 2003;102:644a."},{"key":"2020021215284037300_R73","doi-asserted-by":"crossref","unstructured":"Treon SP, Hunter Z, Branagan AR. Campath-1H in Waldenstrom\u2019s macroglobulinemia [abstract]. Proceedings of the 2004 Clinical Investigator Meeting, Cambridge, Massachusetts, 2004.","DOI":"10.1182\/blood.V104.11.4924.4924"},{"key":"2020021215284037300_R74","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Zomas K, Tsatalas K, et al. Treatment of Waldenstro\u0308m\u2019s macroglobulinemia with single agent thalidomide or with combination of clarithromycin, thalidomide and dexamethasone. Semin Oncol. 2003;30:265\u2013269.","DOI":"10.1053\/sonc.2003.50079"},{"key":"2020021215284037300_R75","doi-asserted-by":"crossref","unstructured":"Weber D, Treon SP, Emmanouilides C, et al. Uniform response criteria in Waldenstrom\u2019s macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom\u2019s Macroglobulinemia. Semin Oncol. 2003;30:127\u2013131.","DOI":"10.1053\/sonc.2003.50037"},{"key":"2020021215284037300_R76","doi-asserted-by":"crossref","unstructured":"Gobbi PG, Bettini R, Montecucco C, et al. Study of prognosis in Waldenstro\u0308m\u2019s macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility. Blood. 1994;83:2939\u20132945.","DOI":"10.1182\/blood.V83.10.2939.2939"},{"key":"2020021215284037300_R77","unstructured":"Morel P, Monconduit M, Jacomy D, et al. Prognostic factors in Waldenstro\u0308m macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood. 2000;96:852\u2013858."},{"key":"2020021215284037300_R78","doi-asserted-by":"crossref","unstructured":"Dhodapkar MV, Jacobson JL, Gertz MA, et al. Prognostic factors and response to fludarabine therapy in patients with Waldenstro\u0308m macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood. 2001;98:41\u201348.","DOI":"10.1182\/blood.V98.1.41"},{"key":"2020021215284037300_R79","doi-asserted-by":"crossref","unstructured":"Facon T, Brouillard M, Duhamel A, et al. Prognostic factors in Waldenstrom\u2019s macroglobulinemia: A report of 167 cases. J Clin Oncol1993;11:1553\u20131558.","DOI":"10.1200\/JCO.1993.11.8.1553"},{"key":"2020021215284037300_R80","unstructured":"Merlini G. Waldenstrom\u2019s macroglobulinemia-clinical manifestations and prognosis. In: Schechter GP, Hoffman R, Schrier SL (eds). Hematology 1999. Washington DC: American Society of Hematology."}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2004\/1\/257\/1634550\/257_282ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2004\/1\/257\/1634550\/257_282ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,30]],"date-time":"2023-04-30T10:31:35Z","timestamp":1682850695000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2004\/1\/257\/18696\/Amyloidosis-and-Waldenstroms-Macroglobulinemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1,1]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2004.1.257","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,1,1]]}}}